https://www.selleckchem.com/pr....oducts/oxidopamine-h
2 log reduction in the TDF group ( = 0.029). Proportion of patients with undetectable HBV DNA (75.7% vs 87.5%), ALT normalization (89.2% Vs 87.5%), HBsAg negativity (25% vs 28.1%), and seroconversion (2.8% vs 3.1%) at 1year were almost similar in both groups with value0.05 for all efficacy end points. There was no HBVR-related mortality in any group. Both ETV and tenofovir are very effective in the treatment of HBVR and reduce the liver-related mortality and morbidity in such patients. Both ETV and tenofovir are ver
Like
Comment
Share
